1. Introduction {#sec1-diagnostics-09-00126}
===============

Diffusion-weighted imaging (DWI), quantified by apparent diffusion coefficients (ADC) besides diagnostic potential can also provide information regarding tumor microstructure \[[@B1-diagnostics-09-00126],[@B2-diagnostics-09-00126],[@B3-diagnostics-09-00126],[@B4-diagnostics-09-00126]\]. This method utilizes the constant random movement of water molecules, called Brownian motion \[[@B4-diagnostics-09-00126]\]. ADC is widely acknowledged to be mainly influenced by the cellularity of tumors and is inversely correlated with cell density in tissues \[[@B3-diagnostics-09-00126]\]. The principle of this is that the cell membrane might hinder the water movement and, therefore, lead to a restriction of diffusion \[[@B5-diagnostics-09-00126]\]. However, important factors are not only cell count but also cell size, cell nucleus size, and membrane permeability \[[@B5-diagnostics-09-00126]\]. Moreover, it was shown that water molecules are also hindered by extracellular components, such as collagen fibers and extracellular matrix \[[@B6-diagnostics-09-00126]\].

DWI is usually acquired by two b-values, a low one, usually 0 s/mm² and a high one, usually 800--1000 s/mm² \[[@B1-diagnostics-09-00126],[@B7-diagnostics-09-00126]\]. The low signal intensity of DWI, up to 200 s/mm² is more sensitive to perfusion than the latter \[[@B1-diagnostics-09-00126],[@B7-diagnostics-09-00126]\]. There is an ongoing debate on whether ADC values can also reflect perfusion related tumor features, such as vessel density \[[@B8-diagnostics-09-00126],[@B9-diagnostics-09-00126],[@B10-diagnostics-09-00126]\]. Presumably, more water molecules can move freely and particularly fast within vessels. Moreover, it was hypothesized that ADC is even has the capacity to reflect factors influencing vascular angiogenesis, for example, expression of vascular endothelial growth factor (VEGF) \[[@B11-diagnostics-09-00126],[@B12-diagnostics-09-00126]\].

Tumor angiogenesis is a hallmark, which provides oxygen and nutrients to tumor cells during cancer progression and metastasis \[[@B13-diagnostics-09-00126]\]. VEGF has been generally regarded as a key factor in angiogenesis \[[@B14-diagnostics-09-00126]\]. It is a protein family consisting of five subtypes with the regulation of the vessel cells by three cell membrane receptors \[[@B14-diagnostics-09-00126]\].

The inhibition of VEGF-A with bevacizumab was the first angiogenesis-related tumor treatment, which nowadays is used for several different tumor entities \[[@B14-diagnostics-09-00126],[@B15-diagnostics-09-00126]\]. Functional imaging biomarker guidance of VEGF treatment might be crucial due to the fact that anti-VEGF therapy might not primarily lead to shrinkage of the tumor, which could be assessed by morphological imaging, but to a devascularization of the tumor assessable only by functional imaging.

The associations between ADC and VEGF have been elucidated in preliminary small studies with incoherent results. Presumably, if routinely acquired ADC values are correlated with VEGF expression in tumors, this might also establish the opportunity for DWI to display treatment response to anti-angiogenesis therapy, which was previously shown in xenograft studies \[[@B11-diagnostics-09-00126],[@B16-diagnostics-09-00126]\].

Therefore, the purpose of the present systematic review and meta-analysis was to review the published studies and to provide data of possible associations between ADC and VEGF expression in several tumors.

2. Materials and Methods {#sec2-diagnostics-09-00126}
========================

Data Acquisition
----------------

MEDLINE and SCOPUS library were screened for associations between ADC values and VEGF expression up to September 2019. The following search words were used: ADC OR apparent diffusion coefficient OR DWI OR Diffusion weighted imaging AND VEGF OR vascular endothelial growth factor. Overall, 68 articles were identified throughout this search process.

The primary endpoint of the systematic review was the correlation between VEGF expression and ADC derived from DWI.

Studies (or subsets of studies) were included if they satisfied all of the following criteria: (1) patients with histopathologically confirmed tumors and expression analysis of VEGF on immunohistochemical stained specimens (2) DWI quantified by ADC (3) correlation analysis.

Exclusion criteria were (1) systematic review (2) case report (3) treatment prediction or histopathology performed after treatment (4) non-English language (5) xenograft or mouse model studies.

After thorough review 14 articles were suitable for the present meta-analysis \[[@B17-diagnostics-09-00126],[@B18-diagnostics-09-00126],[@B19-diagnostics-09-00126],[@B20-diagnostics-09-00126],[@B21-diagnostics-09-00126],[@B22-diagnostics-09-00126],[@B23-diagnostics-09-00126],[@B24-diagnostics-09-00126],[@B25-diagnostics-09-00126],[@B26-diagnostics-09-00126],[@B27-diagnostics-09-00126],[@B28-diagnostics-09-00126],[@B29-diagnostics-09-00126],[@B30-diagnostics-09-00126]\]. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used for the research \[[@B31-diagnostics-09-00126]\]. [Figure 1](#diagnostics-09-00126-f001){ref-type="fig"} displays the PRISMA flow chart of the paper acquisition.

The following data were extracted from the literature: authors, year of publication, study design, tumor entity, number of patients, MRI scanner, b-values of DWI and correlation coefficients.

The methodological quality of the acquired studies was independently checked by two observers (HJM and AS) using the Quality Assessment of Diagnostic Studies (QUADAS 2) instrument, according to previous descriptions \[[@B32-diagnostics-09-00126]\]. [Figure 2](#diagnostics-09-00126-f002){ref-type="fig"} displays the QUADAS results. Most studies showed an overall low risk of bias.

Associations were analyzed by Spearman's correlation coefficient. The Pearson's correlation coefficients in some studies were converted into Spearman's correlation coefficients, as reported previously \[[@B33-diagnostics-09-00126]\].

Furthermore, the meta-analysis was undertaken by using RevMan 5.3 (Computer Program, version 5.3, The Cochrane Collaboration, 2014, The Nordic Cochrane Centre, Copenhagen, Denmark). Heterogeneity was calculated by means of the inconsistency index *I*^2^ \[[@B34-diagnostics-09-00126],[@B35-diagnostics-09-00126]\]. Additionally, DerSimonian and Laird random-effects models with inverse-variance weights were used without any further correction \[[@B36-diagnostics-09-00126]\].

3. Results {#sec3-diagnostics-09-00126}
==========

Overall, the collected 14 articles included 578 patients. In 10 studies (71.4%) 3 T scanners were used, and in four studies (28.6%) 1.5 T scanners. Furthermore, seven studies (50%) had a prospective design, seven studies (50%) had a retrospective design ([Table 1](#diagnostics-09-00126-t001){ref-type="table"}). [Table 2](#diagnostics-09-00126-t002){ref-type="table"} summarizes the included tumor entities. Most frequently, prostate cancer, followed by rectal cancer, cervical cancer and esophageal cancer were identified.

The pooled correlation coefficient between ADC and expression of VEGF *r* = −0.02 \[95% CI −0.26--0.21\], heterogeneity Tau² = 0.17, I² = 89 ([Figure 3](#diagnostics-09-00126-f003){ref-type="fig"}).

The Egger test does not support any linear association between correlation and its weighted standard error (*p* = 0.255) which speaks against publication bias (Q = 121.72), which is supported by the funnel plot ([Figure 4](#diagnostics-09-00126-f004){ref-type="fig"}).

4. Discussion {#sec4-diagnostics-09-00126}
=============

The present systematic review and meta-analysis did not find significant associations between ADC values and the expression of VEGF in tumors.

We identified a positive correlation for four studies including esophageal cancer, ovarian cancer, cervical cancer and pancreatic cancer. On the contrary, there were four studies with an inverse correlation including hepatocellular carcinoma, prostate cancer, rectal cancer and thyroid cancer. In five studies, there were no relationships between VEGF expression and ADC. These findings resulted in an overall non-existing association.

Previously, numerous investigations showed that ADC inversely correlated with cellularity in different malignant and benign lesions \[[@B3-diagnostics-09-00126]\]. Moreover, it was widely acknowledged that DWI may discriminate tumor grades and tumor subtypes. For example, it was shown that benign lesions tended to have higher ADC values than malignant tumors \[[@B37-diagnostics-09-00126],[@B38-diagnostics-09-00126]\].

Furthermore, according to the literature, ADC can also reflect other histopathological features, such as expression of proliferation factor Ki67, epidermal growth factor receptor expression and hypoxia-inducible factor 1-alpha \[[@B25-diagnostics-09-00126],[@B26-diagnostics-09-00126],[@B39-diagnostics-09-00126]\].

However, as mentioned above, there are inconclusive results regarding possible associations between ADC and VEGF expression \[[@B17-diagnostics-09-00126],[@B22-diagnostics-09-00126],[@B24-diagnostics-09-00126]\]. Hypothetically, a positive correlation between the parameters may exist. The rationale is that with higher VEGF expression there are more vessels and, thus, there are more fast protons within the vessels reflected by a higher ADC value.

VEGF is a key factor of tumor neoangiogenesis \[[@B14-diagnostics-09-00126]\]. It has been shown that overexpression of VEGF is an overall indicator of poor survival in various tumor entities emphasizing its clinical importance \[[@B40-diagnostics-09-00126],[@B41-diagnostics-09-00126],[@B42-diagnostics-09-00126]\]. Therefore, it may be beneficial, when imaging can correctly predict VEGF expression of tumors enabling a non-invasive and serial approach compared to bioptic samples.

However, the direct association between VEGF expression and vascularity of tissues and, thus, the overall perfusion is complex. So far, there were no differences in colorectal cancers with high VEGF expression compared to tumors with low expression in regard to microvessel density \[[@B43-diagnostics-09-00126]\]. Yet, in other studies, a moderate to strong correlation was identified between VEGF expression and microvessel density in several tumors \[[@B44-diagnostics-09-00126],[@B45-diagnostics-09-00126],[@B46-diagnostics-09-00126]\]. In a recently published preliminary study investigating head and neck cancer, no correlation between microvessel density and ADC values was identified, which corroborates the present results that DWI is not able to reflect perfusion related histopathology features of tumors \[[@B47-diagnostics-09-00126]\].

When ADC values would be sensitive enough for tissue alterations caused by VEGF expression, predominantly vessel growth and vessel density, DWI may aid in treatment response evaluation to VEGF targeted therapy. In fact, this has been shown in previous studies, for example, in glioblastoma patients and in a glioma experimental tumor model \[[@B48-diagnostics-09-00126],[@B49-diagnostics-09-00126]\]. However, there were also reports indicating that DWI might not be sensitive in this regard \[[@B9-diagnostics-09-00126]\]. Clearly, more studies are needed to validate these findings.

Intravoxel incoherent motion (IVIM), as an advanced DWI technique was introduced, which takes advantage of the perfusion related signal intensity \[[@B7-diagnostics-09-00126]\]. By using several low b-values up to 200 mm²/s, IVIM can provide perfusion related parameters like perfusion fraction f and pseudo diffusion D\*, which might be more sensitive to predict VEGF expression and vessel density of tumors \[[@B7-diagnostics-09-00126]\]. However, the acquisition of IVIM and perfusion parameters is associated with several problems. IVIM protocols take a longer time duration of the sequence, which might hinder the translation into clinical routine. Furthermore, there is still lack of standardization of this technique. This fact hinders the external validations of the reported results.

Possible clinical implications of the present results are that ADC values derived from clinical routine DWI are not able to reflect VEGF expression in tumors. Further on, ADC values might, therefore, not be capable of predicting treatment response assessment with VEGF-targeted therapy.

There are several limitations of the present analysis to address. Firstly, it comprised half of the retrospective studies with known inherent potential bias. Secondly, there were not enough studies to perform tumor-specific sub analyses. Presumably, the heterogeneity shown in the analysis could be induced by differences in tumor types. Thirdly, there were different scanner types and DWI protocols, which have an influence on ADC values and consequently might result in possible bias. Fourthly, there might be possible publication bias, as it is known that negative studies are less likely to be published.

5. Conclusions {#sec5-diagnostics-09-00126}
==============

The present analysis showed that ADC does not correlate with the expression of VEGF and, therefore, cannot be used as a surrogate marker for this histopathological parameter in tumors using a routinely acquired DWI.

Conceptualization: H.-J.M., A.S.; Data curation: H.-J.M., A.W.; Investigation: H.-J.M., A.W.; Methodology: A.W.; Supervision: H.-J.M., A.S.; Validation: H.-J.M., A.W., A.S. Visualization: H.-J.M. Writing---original draft: H.-J.M. Writing---review & editing: A.W., A.S.

This research received no external funding.

The authors declare no conflict of interest.

DWI

Diffusion-weighted imaging

ADC

Apparent diffusion coefficient

VEGF

Vascular endothelial growth factor

IVIM

Intravoxel incoherent motion

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart. An overview of the paper acquisition. Finally, 14 articles were suitable for the analysis.](diagnostics-09-00126-g001){#diagnostics-09-00126-f001}

![Quality Assessment of Diagnostic Studies (QUADAS-2) quality assessment of the included studies. Most studies showed an overall low risk of bias.](diagnostics-09-00126-g002){#diagnostics-09-00126-f002}

![Forrest plots of the correlation coefficients between ADC values and VEGF expression. Overall, 14 studies comprising 578 patients. The pooled correlation coefficient was *r* = −0.02 \[95% CI −0.26--0.21\].](diagnostics-09-00126-g003){#diagnostics-09-00126-f003}

![Funnel plot of the publication bias. There is no significant publication bias identified.](diagnostics-09-00126-g004){#diagnostics-09-00126-f004}

diagnostics-09-00126-t001_Table 1

###### 

Overview of the included studies.

  Author, Year                                           Country       Design          Number of Patients   Tumor Entity               Field Strength (T)   *b*-Values (s/mm²)
  ------------------------------------------------------ ------------- --------------- -------------------- -------------------------- -------------------- --------------------
  Aoyagi et al. 2012 \[[@B17-diagnostics-09-00126]\]     Japan         prospective     17                   Esophageal cancer          1.5                  0;1000
  Cong et al. 2019 \[[@B30-diagnostics-09-00126]\]       China         retrospective   52                   Esophageal cancer          3                    0;800
  Heo et al. 2010 \[[@B18-diagnostics-09-00126]\]        South Korea   retrospective   27                   Hepatocellular carcinoma   1.5                  0;1000
  Huang et al. 2014 \[[@B19-diagnostics-09-00126]\]      China         retrospective   36                   Hepatocellular carcinoma   3                    0;800
  Lindgren et al. 2017 \[[@B20-diagnostics-09-00126]\]   Finland       prospective     40                   Ovarian cancer             3                    0;300;600
  Liu et al. 2013 \[[@B21-diagnostics-09-00126]\]        China         prospective     56                   Cervical cancer            1.5                  0;100;0;3000
  Ma et al. 2018 \[[@B22-diagnostics-09-00126]\]         China         prospective     39                   Prostate cancer            3                    0;800
  Meng et al. 2016 \[[@B23-diagnostics-09-00126]\]       China         prospective     91                   Rectal cancer              3                    0;800
  Meyer et al. 2018 \[[@B24-diagnostics-09-00126]\]      Germany       retrospective   11                   Rectal cancer              3                    0;1000
  Meyer et al. 2018 \[[@B25-diagnostics-09-00126]\]      Germany       retrospective   32                   Head and neck cancer       3                    0;800
  Meyer et al. 2018 \[[@B26-diagnostics-09-00126]\]      Germany       retrospective   18                   Cervical cancer            3                    0;1000
  Oto et al. 2011 \[[@B27-diagnostics-09-00126]\]        USA           retrospective   73                   Prostate cancer            1.5                  0;1500
  Shi et al. 2017 \[[@B28-diagnostics-09-00126]\]        China         prospective     58                   Thyroid cancer             3                    0;1000
  Xie et al. 2015 \[[@B29-diagnostics-09-00126]\]        China         prospective     28                   Pancreatic cancer          3                    0;1000

diagnostics-09-00126-t002_Table 2

###### 

Overview of the included tumor entities.

  Tumor Type                 *n* (%)
  -------------------------- ------------
  Prostate cancer            112 (19.4)
  Rectal cancer              102 (17.7)
  Cervical cancer            74 (12.8)
  Esophageal cancer          69 (11.9)
  Hepatocellular carcinoma   63 (10.9)
  Thyroid cancer             58 (10.0)
  Ovarian cancer             40 (6.9)
  Head and neck cancer       32 (5.5)
  Pancreatic cancer          28 (4.9)
  Total                      578 (100)
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